Here, we discuss the development and application of multiplex immunofluorescence-based biomarker strategies to study the tumour microenvironment in lymphoma patients, exploring how these approaches can help to identify immune cell interactions.

Diagnostic biomarkers offer a crucial means of tracking disease spread and progression. Here, we explore their application in age-related diseases, as well as inflammatory diseases such as Crohn’s.

Blood is a rich source for biomarker development, and CTCs are increasingly proving themselves to be valuable in cancer prognosis and treatment prediction.

While the complexities associated with identifying tumour state and coordinating an effective immunotherapeutic response are many, pioneering healthcare providers are rising to the challenge.

An understanding of the complex pathologies involved in patients with neurodegenerative diseases is integral to the identification of biomarkers and potential treatment methods for individuals who suffer from Alzheimer’s, Parkinson’s, and ALS. Here, we look at the development of dedicated biomarker strategies for helping to combat neurodegeneration.

While the integration of AI in digital pathology will require a concerted push from those in the industry, the ability to rapidly process large amounts of tissue data with a high degree of accuracy makes it a potentially invaluable resource for diseases which are highly heterogeneous.

Milena Dumont Milutinovic, Senior Manager of Field Applications at Quanterix, walks through the company's ultrasensitive biomarker assay technology.

While constraints on the integration of NGS approaches in selection biomarker validation for new treatments still need ironing out, their benefits in assisting clinical trial progress are undeniable.

Highly involved treatment scenarios and prognostics are required to properly assess best-practice approaches for investigating issues posed by NASH and liver cirrhosis. Surrogate biomarkers present a less invasive approach to assessing these outcomes.

The global race to develop, trial, and distribute a vaccine for Covid-19 may have permanently accelerated the development of future therapeutics, including treatments for cancer.

How can we better define patient-centric clinical trials within the drug development process?

The potential oncolytic applications of Salmonella ZH9 include its use in mitigating diseases such as bladder cancer, with a demonstrated therapeutic effect in cancer models.

Christopher Conn, Director of Diagnostics Strategy at Amgen, leads a Discussion Group on patient testing and engagement in biomarker clinical trials.

Multiplex immunofluorescence is gaining prevalence in oncology diagnostics; what makes it so effective, and how is it being brought into the clinic?

Beverley Patterson, Clinical Science Director at Ono Pharma UK Ltd, leads a Discussion Group on harnessing biomarker technologies to improve disease detection and tracking.

Smartphones, laptops and other household electronic devices could be optimised for the early detection of neurodegenerative diseases such as Alzheimer’s. Preventative monitoring approaches such as these could provide another avenue of detection to abet the provision of treatment.

Key opinion leaders talk understanding the scientific and regulatory considerations for the qualification of biomarkers.

In this Commentary, we explore how non-invasive biomarkers may be used to diagnose pre-symptomatic NASH in patients without them undergoing invasive biopsies.